B29 gene transfer into chronic lymphocytic leukemia B cells

Melinda S. Gordon*, Anne Catherine Fluckiger, David J. Rawlings, Alexis A. Thompson, Randolph Wall

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Chronic lymphocytic leukemia (CLL), the most common leukemia in the United States and Europe, is characterized by non-responsive immature B cells with low or no surface B Cell Receptor (BCR, IgM). The BCR accessory protein, B29, is critical to receptor surface expression and signal transduction. Aberrant B29 expression is the most consistent defect associated with CLL and may result in B cells that do not recognize or respond to antigen. We are developing a system to rescue BCR assembly and signaling by B29 gene transfer. We have recently established in vitro culture of B-CLL cells. B cells from CLL patients can proliferate when co-cultured with CD40-ligand stroma and IL-4. A recombinant Vaccinia vector has been constructed that is capable of infecting B-CLL cells and produces high levels of B29 protein in B29- fibroblast, T and plasmacytoma cell lines. B-CLL cells in co-culture will be infected with the Vaccinia-B29 vector and tested for the presence of B29 protein, restoration of BCR surface expression and early signaling events, including tyrosine phosphorylation and calcium flux.

Original languageEnglish (US)
JournalFASEB Journal
Issue number5
StatePublished - Mar 20 1998

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics


Dive into the research topics of 'B29 gene transfer into chronic lymphocytic leukemia B cells'. Together they form a unique fingerprint.

Cite this